Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker.
Status unconfirmed · Phase 4
Conditions studied: Vitrectomy, Macular Pucker, Retinal Edema
In brief
Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg inserts following 27 gauge vitrectomy with internal limiting membrane peel
Key facts
- Study ID
- NCT04501367
- Run by
- Kovach Eye Institute
- People needed
- 60
- Starts
- 2021-04-27
- Expected to finish
- 2024-12-31
- Last updated by the study team
- 2023-06-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Kovach Eye Institute — Elmhurst, Illinois, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.